×
Abstract P5-11-04: Therapy-induced priming of natural killer cells predicts patient-specific tumor rejection in multiple breast cancer indications
http://cancerres.aacrjournals.org/content/78/4_Supplement/P5-11-04

Jul 19th, 2018 - Background: Predicting patient-specific clinical response to anticancer therapy is the holy grail of treatment-selection. It is now clear that response or resistance to therapy depends on the heterogeneous tumor microenvironment, which is comprised of malignant cells, normal stroma, soluble ligands, and tumor-immune contexture; attributes that are unique to each individual patient. This is part...

Abstract P4-08-05: Impact of common polymorphisms of CYP19A1 and UGT2B17 gene deletion on early endocrine-responsive postmenopausal breast cancer
http://cancerres.aacrjournals.org/content/78/4_Supplement/P4-08-05

Jul 23rd, 2018 - Background Polymorphisms of genes involved in estrogen production have been linked to breast cancer risk, prognosis and treatment response. Polymorphisms of the aromatase gene CYP19A1 influence its activity. The UGT2B17 catalyzes glucuronic acid transfer to a variety of substrates, including steroids and drugs like the aromatase inhibitor exemestane. We investigated the impact of two variants o...

Abstract P1-06-12: Optimizing the use of oncotype Dx in early breast cancer
http://cancerres.aacrjournals.org/content/78/4_Supplement/P1-06-12

Jul 31st, 2018 - Background: Oncotype Dx (ODX) prognosticates the risk of recurrence and predicts the benefit of adjuvant chemotherapy in estrogen-receptor-positive breast cancer (BC). However, its cost makes it prohibitive for many health care systems. Our objective was to develop a model that uses routine clinical and pathological parameters to identify ODX high risk patients which require adjuvant chemothera...

Abstract P1-06-07: Mayo clinic TNBC outcome calculator: A clinical calculator to predict disease relapse and survival in women with triple-negative breast cancer
http://cancerres.aacrjournals.org/content/78/4_Supplement/P1-06-07

Aug 4th, 2018 - Purpose: Triple negative breast cancer (TNBC) is an aggressive breast cancer subtype with substantial risks of disease recurrence. While cytotoxic chemotherapy is commonly administered and reduces recurrence, disease outcomes vary considerably and few prognostic tools are available for risk stratification for TNBC patients. We constructed and validated clinical calculators for invasive-disease ...

Abstract P1-06-10: Correlative analysis of breast cancer index (BCI) restratification of 21-gene recurrence score (RS) in patients with hormone receptor-positive (HR+), node-negative breast cancer
http://cancerres.aacrjournals.org/content/78/4_Supplement/P1-06-10

Aug 5th, 2018 - Background: In a cross-stratification analysis performed within the TransATAC cohort, Breast Cancer Index (BCI) and 21-gene Recurrence Score (RS) had a concordance of 58.2% (Sestak et al., Clin Cancer Res, 2016). Restratification by BCI of the low and intermediate RS risk groups led to subgroups with significantly different rates (P < 0.001 and P = 0.003, respectively); in contrast, restratifie...

Abstract P3-08-08: Prognostic associations of plasma hepcidin in early breast cancer (BC)
http://cancerres.aacrjournals.org/content/78/4_Supplement/P3-08-08

Aug 15th, 2018 - Background: Intra-tumor RNA expression of hepcidin has been linked to adverse metastasis-free survival in women with early BC, but the prognostic implications of this inflammatory marker and iron-regulating peptide are unknown. Methods: Using an ELISA assay, we measured plasma hepcidin in the banked blood of 518 women who were recruited from 1989-1996 for a prospective cohort study regarding di...

Abstract P3-08-13: Serum thymidine kinase activity is an independent prognostic factor for progression-free and overall survival in women with metastatic breast cancer
http://cancerres.aacrjournals.org/content/78/4_Supplement/P3-08-13

Aug 21st, 2018 - Introduction: Although prognosis and treatment of metastatic breast cancer (MBC) have improved over the last years, there is still an unmet clinical need for more precise prognostic and treatment monitoring tools. Liquid-based markers are preferred since they reflect real-time tumor progression and are not dependent on repeated invasive tissue biopsies. Thymidine kinase 1 (TK1) is an enzyme inv...

Abstract P5-18-01: Extended continuous vs intermittent adjuvant letrozole in postmenopausal women with lymph node-positive, early breast cancer (IBCSG 37-05/BIG 1-07 SOLE): Impact on patient-report...
http://cancerres.aacrjournals.org/content/78/4_Supplement/P5-18-01

Aug 24th, 2018 - Background: SOLE efficacy results presented at ASCO 2017 showed that extended intermittent vs continuous letrozole for 5 years did not improve disease-free survival in postmenopausal women who had received 4-6 years of adjuvant endocrine therapy for hormone-receptor positive (HR+), lymph-node positive breast cancer. Previous studies showed that the burden by symptoms related to endocrine therap...

Abstract P5-18-04: Bridging gaps in breast cancer care: A pilot forum for mental health professionals
http://cancerres.aacrjournals.org/content/78/4_Supplement/P5-18-04

Aug 26th, 2018 - Introduction: Supporting the emotional needs of women diagnosed with breast cancer is a recognized priority for cancer clinicians and a core component of high quality care and survivorship programs. We hypothesized that mental health professionals would benefit from an educational program directed to enhance their practical knowledge of breast cancer. Methods: We designed an innovative educatio...

Abstract P6-11-02: Voice of cancer patients: Analysis of patient concerns regarding scalp cooling devices for prevention of chemotherapy induced alopecia
http://cancerres.aacrjournals.org/content/78/4_Supplement/P6-11-02

Aug 28th, 2018 - Adjuvant chemotherapies for breast cancer cause hair loss in majority of patients. Although Chemo Induced Alopecia (CIA) is temporary, is distressing for many patients and about 7% patients treated with docetaxel experience permanent hair loss. Scalp cooling devices (SCDs) have been shown to reduce hair loss in patients receiving chemo. Many patients share their experiences in online forums as ...

Abstract P6-11-06: Efficacy of scalp cooling in preventing chemotherapy-induced alopecia in breast cancer patients: A retrospective, comprehensive review of 330 cases of Brazil
http://cancerres.aacrjournals.org/content/78/4_Supplement/P6-11-06

Aug 29th, 2018 - Background: Chemotherapy-induced alopecia (CIA) is a distressing adverse effect of many chemotherapy (CT) agents. New strategies for prevention of CIA have been studied. Scalp cooling has been reported to prevent CIA. We conducted a retrospective study aimed to assess the efficacy of scalp cooling in preventing CIA among women receiveing chemotherapy for breast cancer. Methods: Was included cli...

Abstract P6-11-08: Chemotherapy-induced peripheral neuropathy and quality of life among breast cancer survivors
http://cancerres.aacrjournals.org/content/78/4_Supplement/P6-11-08

Aug 30th, 2018 - Introduction: Breast cancer survivors are at risk for long-term chemotherapy-induced peripheral neuropathy (PN), which has few treatment options and can affect quality of life. We examined 1) the presence and severity of PN and its correlates among 442 metastatic (MBC) and 238 breast cancer (BC) survivors who received chemotherapy, and 2) provider communication, preparation, and confidence in m...

Abstract P6-11-14: Safety and effectiveness of sensor-controlled scalp cooling to prevent alopecia in primary breast cancer patients receiving neoadjuvant or adjuvant epirubicin, taxanes, or both
http://cancerres.aacrjournals.org/content/78/4_Supplement/P6-11-14

Sep 9th, 2018 - Background: Chemotherapy (Ctx)-induced alopecia (CIA), produces a deep psychological distress in many women involved. Sensor-controlled scalp cooling (SCSC) is now approved by the FDA due to both its effectiveness and safety to prevent CIA demonstrated in two randomized trials in patients (pts) with primary breast cancer (PBC). However, SCSC is still infrequently used in many countries due to p...

Abstract P5-22-07: Upgrade to high risk lesions, in situ and invasive cancer among women with benign papillary lesions diagnosed on image-guided core needle biopsy (IGCNB)
http://cancerres.aacrjournals.org/content/78/4_Supplement/P5-22-07

Dec 15th, 2018 - Background: Currently there is no consensus regarding the management of benign papillary breast lesions diagnosed on IGCNB. Recommendations vary as to whether all IGCNB papillary lesions require surgical excision or if IGCNB alone is adequate to confirm a benign diagnosis and patients can be followed with imaging. Aims: To estimate percentage of patients with benign papilloma on IGNB who on sur...

Abstract P5-22-22: Breast tumor location in BRCA mutation carriers and implications for prevention
http://cancerres.aacrjournals.org/content/78/4_Supplement/P5-22-22

Dec 16th, 2018 - Introduction: Close to 65% of BRCA mutation carriers do not choose prophylactic mastectomy, despite their high breast cancer risk. Breast reduction mammoplasty is a surgical technique shown to reduce breast cancer risk and can be modified to target specific areas of the breast. We wondered if a majority of tumors in BRCA mutation carriers would be confined to one quadrant, allowing for the use ...

Abstract P6-11-18: Ten year trends in antiemetic prescribing in cancer patients receiving highly emetogenic chemotherapy (HEC)
http://cancerres.aacrjournals.org/content/78/4_Supplement/P6-11-18

Sep 12th, 2018 - Purpose: Prevention of chemotherapy-induced nausea and vomiting (CINV) is essential to preserve quality of life in cancer patients receiving highly emetogenic chemotherapy (HEC) such as doxorubicin-cyclophosphamide (AC) or cisplatin. Recently, new drugs (e.g. fosaprepitant and newer neurokinin 1 receptor antagonists [NK1RAs], rolapitant and netupitant) and updated guidelines for antiemetic use ...

Abstract P5-22-20: Oncologic safety of endoscopic assisted breast surgery compared with conventional breast surgery: An analysis of 1295 primary operable breast cancer patients from single institute
http://cancerres.aacrjournals.org/content/78/4_Supplement/P5-22-20

Dec 17th, 2018 - Background:Endoscopy-assisted breast surgery (EABS) performed through minimal axillary and/or periareolar incisions is a possible alternative to open surgery for certain patients with breast cancer. In this study, we report the oncologic safety results of EABS compared with conventional breast surgery (CBS). Methods: The medical records of patients who underwent EABS for breast cancer during th...

Abstract P5-22-23: Electrochemotherapy : A new local therapy for cutaneous metastases of breast cancer
http://cancerres.aacrjournals.org/content/78/4_Supplement/P5-22-23

Dec 18th, 2018 - Background : Electrochemotherapy (ECT) is a new local therapy combining the administration of an intravenous chemotherapy (bleomycin) followed by the direct application of electric pulses by an electrode to the treated areas. Electric pulses transiently permeabilize the membrane of the tumor cell ( electroporation), improving intracellular diffusion of a poorly permeant chemotherapeutic agent, ...

Abstract P5-22-04: Efficacy of thoracic paravertebral block for reducing acute post-mastectomy pain
http://cancerres.aacrjournals.org/content/78/4_Supplement/P5-22-04

Dec 19th, 2018 - Background: Mastectomy is associated with acute and chronic postoperative pain. This study investigated the efficacy of thoracic paravertebral block (TPB) compared to local anesthetic of surgical wound (LASW) in breast cancer patients undergoing mastectomy. Methods: This phase 3, randomized controlled, single blind, parallel arms and superiority clinical trial aimed to evaluate the efficacy of ...

Abstract P6-13-04: IMPACt trial: MammaPrint and BluePrint molecular subtyping guide treatment decisions in breast cancer
http://cancerres.aacrjournals.org/content/78/4_Supplement/P6-13-04

Sep 16th, 2018 - Background: IMPACt is a prospective, case-only study to measure the effect of MammaPrint (MP) and BluePrint (BP) on treatment decisions in breast cancer patients. Here, we report the results of the primary objective in women aged ≥18 years with histologically proven invasive stage I-II, hormone receptor (HR) positive, and HER2-negative breast cancer. Methods: The study included 369 women from 1...